| Host: |
Rabbit |
| Applications: |
IHC/IF |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit monoclonal antibody anti-Recombinant-SOX9 is suitable for use in Immunohistochemistry and Immunofluorescence research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
SR0521 |
| Conjugation: |
Unconjugated |
| Formulation: |
PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Purification: |
Recombinant Expression and Affinity purified |
| Dilution Range: |
IHC/IF (H, M, R) 1:200-1:400 |
| Storage Instruction: |
Store at-20C for up to one year, and avoid repeated freeze-thaw cycles. |
| Gene Symbol: |
SOX9 |
| Gene ID: |
6662 |
| Uniprot ID: |
SOX9_HUMAN |
| Immunogen: |
KLH conjugated Synthetic peptide corresponding to Human SOX9 |
| Function | Transcription factor that plays a key role in chondrocytes differentiation and skeletal development. Specifically binds the 5'-ACAAAG-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis, including cartilage matrix protein-coding genes COL2A1, COL4A2, COL9A1, COL11A2 and ACAN, SOX5 and SOX6. Also binds to some promoter regions. Plays a central role in successive steps of chondrocyte differentiation. Absolutely required for precartilaginous condensation, the first step in chondrogenesis during which skeletal progenitors differentiate into prechondrocytes. Together with SOX5 and SOX6, required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes, the second step in chondrogenesis. Later, required to direct hypertrophic maturation and block osteoblast differentiation of growth plate chondrocytes: maintains chondrocyte columnar proliferation, delays prehypertrophy and then prevents osteoblastic differentiation of chondrocytes by lowering beta-catenin (CTNNB1) signaling and RUNX2 expression. Also required for chondrocyte hypertrophy, both indirectly, by keeping the lineage fate of chondrocytes, and directly, by remaining present in upper hypertrophic cells and transactivating COL10A1 along with MEF2C. Low lipid levels are the main nutritional determinant for chondrogenic commitment of skeletal progenitor cells: when lipids levels are low, FOXO (FOXO1 and FOXO3) transcription factors promote expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation. Mechanistically, helps, but is not required, to remove epigenetic signatures of transcriptional repression and deposit active promoter and enhancer marks at chondrocyte-specific genes. Acts in cooperation with the Hedgehog pathway-dependent GLI (GLI1 and GLI3) transcription factors. In addition to cartilage development, also acts as a regulator of proliferation and differentiation in epithelial stem/progenitor cells: involved in the lung epithelium during branching morphogenesis, by balancing proliferation and differentiation and regulating the extracellular matrix. Controls epithelial branching during kidney development. |
| Protein Name | Transcription Factor Sox-9 |
| Database Links | Reactome: R-HSA-3769402Reactome: R-HSA-8878166Reactome: R-HSA-9690406Reactome: R-HSA-9856649 |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Transcription Factor Sox-9 antibodyAnti-SOX9 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
